<DOC>
	<DOCNO>NCT02275156</DOCNO>
	<brief_summary>The primary objective study evaluate pharmacokinetics evolocumab single 140 mg subcutaneous ( SC ) dose adult normal renal function severe renal impairment end-stage renal disease ( ESRD ) receive hemodialysis .</brief_summary>
	<brief_title>Estimation Study Assess Effect Severe Renal Impairment End-stage Renal Disease Hemodialysis Pharmacokinetics Evolocumab</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>Body mass index ( BMI ) ≥ 18 ≤ 35 kg/m² screening . Subjects lowdensity lipoprotein cholesterol ( LDLC ) 70190 mg/dL ( inclusive ) statin therapy . Other inclusion criterion may apply . Subject current prior history statin intolerance Subject previously receive Evolocumab ( AMG 145 ) investigational therapy direct PCSK9 Known substance abuse ( eg , alcohol , licit illicit drug ) within 12 month day 1 Testing positive alcohol and/or drugsofabuse screening , day 1 , day 1 ( alcohol ) History hypersensitivity allergic reaction mammalianderived drug preparation Known sensitivity active substance excipients administer dosing , eg , carboxymethylcellulose Other exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Subjects normal renal function severe renal impairment ( RI ) end stage renal disease ( ESRD ) receive hemodialysis</keyword>
</DOC>